Reprint

The New Branding Model: From Blockbusters to Targeted Therapies
By John Mack

The pharmaceutical industry is in the midst of a “perfect storm,” according to Francoise Simon, Ph.D., professor of marketing at the Columbia University Graduate School of Business and co-author of the book “Building Global Brands: Taking Biotechnology to Market.” She was speaking at the World Congress on Pharmaceutical Marketing held in Philadelphia, PA, on May 25-27, 2004.

At an Inflection Point
The traditional blockbuster approach (products with more than $1 billion in annual sales) is yielding diminishing returns while post-genomic research is driving towards personalized medicine. The biopharma industry, contends Dr. Simon, is at an inflection point where the emphasis on blockbusters and traditional mass-marketing is being challenged by the new paradigm of personalized medicine.

Dr. Simon contends that Pharma company drug portfolios are shifting away from mass-market blockbusters toward more targeted therapies, which are effective against small patient groups segmented according to genotype. This model, according to Simon, requires a fundamental reorganization of the biopharma value chain, from discovery to manufacturing and marketing.

Specifically, sales and marketing personnel must be retrained and reorganized to accommodate the new targeted branding model. This model requires evidence-based, science-driven positioning in which the sales force needs to be highly trained and complemented with medical liaisons. In addition, Simon says, targeted therapy marketing must establish close links with patient advocacy groups and put a greater focus on online communications to reach these targeted patients who, as a rule, are more “Internet-positive” than the general population.

Biologics are Big Business
Biotechnology is a big business and already produces several “neo-blockbusters.” In 2002, eight biologics were in the billion-dollar sales club.
manding positive outcomes based on pharmacoeconomic studies, and physicians who want more emphasis on efficacy and safety. Consumers, who have direct access to scientific literature via the Internet, are another important factor not to be dismissed.

Experienced-based marketing will continue to be effective in noncritical categories such as allergies. For critical areas like oncology, however, evidence-based marketing will be demanded.

**Lamisil: A Case Study**

Cynthia Hogan, Senior Vice President and Head of Novartis Ophthalmics North America, presented at the same meeting. Her presentation, “Transferring Mass Market Skill Sets to Targeted Brands,” used the Lamisil marketing strategy as a case study for evidence-based marketing of targeted or specialty brands.

Some mass-marketing skills are transferable to specialty brands, but most are not (see TABLE, next page). Segmentation analysis and branding

Managed care did not want to pay for cosmetic treatments and many physicians ignored the problem in the first place. Clearly, the Lamisil marketing message had to emphasize that onychomycosis was an infection and that Lamisil was the cure. Competing messages, however, from external toenail products—“treat the infection from outside, where it grows”—led to consumer confusion.

In 2003, the Lamisil marketing strategy was reshaped to put more emphasis on disease education with a branded campaign featuring the Digger icon—you know, that wacky dermatophyte that lives deep under the nail! The result was a significant increase in total prescriptions in 2003 vs. 2000.

**Absolute Shift to Personalized Medicine Unlikely**

An absolute shift from blockbuster mentality to targeted treatment mentality is not likely, says Dr. Simon, because several factors will continue to

<table>
<thead>
<tr>
<th>Experience-based Marketing</th>
<th>Evidence-based Marketing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physicians</strong></td>
<td></td>
</tr>
<tr>
<td>• Messages focused on drug dosage, delivery, and convenience;</td>
<td>• Messages focused on hard clinical endpoints of efficacy, safety, and tolerability;</td>
</tr>
<tr>
<td>• Supported by CME, patient programs, practice management;</td>
<td>• Key opinion leader and medical liaison influencers;</td>
</tr>
<tr>
<td>• Trusted company and sales rep relationship</td>
<td>• Formulary inclusion and pharmacoeconomic factors</td>
</tr>
<tr>
<td><strong>Consumers</strong></td>
<td></td>
</tr>
<tr>
<td>• Messages focused on delivery, convenience, quality of life improvement;</td>
<td>• Messages focused on efficacy, safety, tolerability;</td>
</tr>
<tr>
<td>• Brand loyalty;</td>
<td>• Supported by disease-related education, especially via Internet;</td>
</tr>
<tr>
<td>• Strong traditional media influence;</td>
<td>• Physicians, pharmacists, nurses are influencers;</td>
</tr>
<tr>
<td>• Supported by corporate reputation and disease-related experience</td>
<td>• Reimbursement and copay issues</td>
</tr>
</tbody>
</table>

message skills, for example, are transferable whereas the DTC skill set is not. Specialty marketing requires a direct-to-patient (DTP) focus and Hogan believes “there is still a lot we can do as an industry to learn how to communicate directly to the patient in terms that they accept.”

In 2002 the Lamisil market dynamics categorized onychomycosis (toenail infection), the indicated condition for Lamisil, as a cosmetic problem.

The cost of developing a prescription drug averages $897 million, according to the Tufts Center for the Study of Drug Development.

Genomic technologies have a long payoff, high R&D costs, and are risky in the short term

There is continued pressure to develop new blockbusters as patents expire on several drugs worth $100 billion this decade.
• Megamergers will drive the need for continued double-digit growth in sales or about $1 billion in new sales each year.
• Marketing and sales costs have increased especially due to DTC advertising and increased difficulty gaining access to physicians.

Possible Future Scenarios
Consumer attitudes and technology will ultimately determine what the future holds for biopharma companies. Applying scenario planning principles to this industry (see “Scenarios on the Future of Pharma Marketing: No Time Like the Present to Think the Unthinkable,” PMN Reprint 33-01) yields four different possible scenarios when plotting consumer attitudes vs. technology outcomes (see CHART, right):

1. The convergence of positive consumer attitudes and positive technology outcomes would lead to personalized medicine.
2. Consumer ambivalence, however, combined with a positive technology outcome would result in a hybrid system in which both traditional mass-market drugs and targeted therapies coexist.
3. On the other hand, if technology breakthroughs would lag while the consumer outlook was positive, then the current situation would prevail (status quo scenario).
4. Finally, if both technology outcomes and consumer attitudes are negative, that would reinforce skepticism about traditional medicine and foster further inroads by alternative medicine.

So, toward which scenario are we headed? Consider the following:

On the one hand, consumer attitudes towards biotechnology are highly conflicted regarding biotechnology. This is evident in the various worldwide regulations regarding biotech research (e.g., gene therapy, stem cell research, cloning, etc.).

On the other hand, while genomic research has successfully identified many targets for new drug therapies, biotech companies are overwhelmed by the abundance, according to several experts speaking at BIO 2004, an industry conference held in San Francisco in June, 2004. Moreover, research is costly and failure rates are high. According to a recent report by the FDA (“Innovation or Stagnation? -- Challenge and Opportunity on the Critical Path to New Medical Products”), “[t]here is great concern about the ability to bring the hoped-for outcomes of basic research advances -- much awaited new treatments -- to patients. There is concern that hoped-for advances in medicine and new treatments for diseases may never materialize.”

Continues on next page…
“With so much promising technology in development in the clinical labs, ranging from engineered tissues to new kinds of biologicals and genomics-based treatments, we need to turn the process of bringing these technologies to patients from a costly and time-consuming art form to a well-understood science,” said FDA Commissioner Mark B. McClellan, M.D., Ph.D.

In other words, we may be headed toward the negative-negative territory (alternative medicine) area of the scenario chart. This, of course, is the worst possible outcome for the pharmaceutical industry.

Pharma Marketing News

Experts Consulted and/or Cited In Articles

The following experts were mentioned or consulted in the preparation of articles for this issue.

- Francoise Simon, Ph.D., Professor, Columbia Business School.

Resource List

The following resources were consulted in the preparation of this issue or cited within this issue.

Pharma Marketing News

Pharma Marketing News—the First Forum for Pharmaceutical Marketing Experts—is published monthly by VirSci Corporation except for August. It is distributed electronically by email and the Web to members of the Pharma Marketing Network (www.pharma-marketing.com).

VirSci Corporation specializes in pharmaceutical marketing intelligence and best practices, development of sponsored newsletters and other educational programs, and consulting in privacy and HIPAA. Our goal is to help our clients gain access to their clients and do business via the Internet more effectively, with greater return on

Publisher & Executive Editor

John Mack
VirSci Corporation
www.virsci.com
PO Box 760
Newtown, PA 18940
215-504-4164, 215-504-5739 FAX
mailto:editor@pharmamarketingnews.com

Advisory Board

Jack Pfister
Director, Business Development, Bruce Leeb & Company
Mark Schmukler
Managing Partner, Sagefrog Marketing Group, LLC
Harry Sweeney
Chairman, CEO, Dorland Global Health Communications
Richard Vanderveer, PhD
Chairman & CEO, V2

Subscribe to Pharma Marketing News

Pharma Marketing News (PMN) is the FREE monthly e-newsletter of the Pharma Marketing Network. Each month, except August, an executive summary of the newsletter with links to the full text pdf version is delivered to subscribers by e-mail. By subscribing to PMN, you agree to receive additional occasional promotional e-mail messages as well as newsletter highlights. If you do not wish to receive any promotional e-mail messages but would rather pay a small fee for full text reprints of selected individual articles, please check REPRINT NOTIFICATION SERVICE as your option below. Through the Reprint Notification service, you receive only one monthly executive summary (no separate promotional messages) by e-mail with information about ordering the full-text versions of articles. We do not sell or share your personal information with third parties.

RED=REQUIRED INFORMATION

FIRST NAME: _______________________________ LAST NAME: ______________________________________
JOB TITLE: ___________________________________ COMPANY: ______________________________________
COUNTRY: __________________________________________________________________________________
E-MAIL ADDRESS: ____________________________________________________________________________
E-MAIL FORMAT PREFERENCE: ___ HTML ___ TEXT ___ NONE

☐ SUBSCRIBE ME TO THE REPRINT NOTIFICATION SERVICE ONLY!
I understand that I will receive only one (1) e-mail message per month with information about ordering, for a low fee, selected article reprints (electronic pdf files) from the current issue of the newsletter. I have no obligation to order or pay for any reprint whatsoever.

THE FOLLOWING INFORMATION IS OPTIONAL (For our internal use only. We do not sell or rent this information to third parties)

ADDRESS: __________________________________________________________________________________
CITY: ______________________ STATE/PROV:______________ POSTAL CODE: ________________________
PHONE: ______________________ FAX: ____________________________________________________________

Mail or fax to: VirSci, PO Box 760, Newtown, PA 18940, 215-504-5739 (Fax)